DealsMay 13, 2026, 04:09 PM
Allogene Therapeutics Terminates Overland License, Restructures Equity
AI Summary
Allogene Therapeutics terminated its Exclusive License Agreement with Overland Therapeutics, effective May 12, 2026, which previously granted Overland rights to develop and commercialize four allogeneic CAR T cell therapies in Greater China, Taiwan, South Korea, and Singapore. As part of the termination, Allogene surrendered a portion of its equity in Overland for no consideration, reducing its stake to approximately 3%. Concurrently, Allogene reported a Q1 2026 net loss of $42.6 million and provided positive clinical updates for its ALPHA3 trial (cema-cel) and RESOLUTION trial (ALLO-329), alongside an extended cash runway into Q1 2029 due to a $200.4 million public offering.
Key Highlights
- Terminated Exclusive License Agreement with Overland Therapeutics for four CAR T cell therapies.
- Allogene surrendered a portion of its equity in Overland, reducing its stake to approximately 3%.
- Reported Q1 2026 net loss of $42.6 million, or $0.18 per share.
- Ended Q1 2026 with $266.9 million in cash, cash equivalents, and investments.
- April public offering added $200.4 million in gross proceeds, extending cash runway into Q1 2029.
- ALPHA3 trial showed 58.3% (7/12) MRD clearance in cema-cel arm vs. 16.7% (2/12) in observation arm.
- Increased 2026 operating cash expense guidance from ~$150 million to ~$165 million.